Greater Munich Biotech Region - IZB

comparisonsneezeBiotechnology

Dec 1, 2012 (5 years and 3 months ago)

760 views

Life Sciences in
Greater Munich
Biotech Region
Playing in top position in Europe’s Biotech Champions League
A special supplement published by Life Science CLUSTERS magazine
Biotechnology
Cluster Bavaria
Germany's No. 1
Munich: Top Location in Germany
4 approved Biotech-Drugs
120 Biotech, 400 LifeScience companies
BigDeals with Pfizer, Novartis...
world leading production plant
(Roche in Penzberg)
more than 30.000 employees
in business and science
Your gateway to excellence
Biotechnology in Bavaria and i.e.
in the Greater Munich Area is
managed and coordinated by Bio
M
.
Find out more about the companies,
job opportunities, news:
www.bio-m.org
www.biotech-bavaria.de
3
Editorial
Greater Munich Biotech Region
GSK
9
Pieris
12
Mikrogen
15
Toplab
18
Ibidi
20
Bio-Europe
22
Editorial
3
Academic Collaboration
5
Representation
6
Incubator
8
Pharmaceuticals
9
GSK
Company Profiles: Drug Discovery
10
MediGene, Wilex, Fresenius Biotech, Trion Pharma, Pieris,
Micromet, Emergent Biosolutions, Octagene, SuppreMol,
Corimmun, Mikrogen
Discovery Platforms
16
MorphoSys, Kinaxo Biotechnologies, 4SC,
Proteros biostructures, Toplab
Biopharm Materials
19
AMSilk, Biontex Laboratories
Specialist Services
20
Coriolis Pharmaservice, ibidi, Origenis, Sirion Biotech
Event Preview; BIO-Europe 2010
22
The views and opinions expressed in this publication
are not necessarily those of the publishers
Produced on behalf of Bio
M
Biotech Cluster Development GmbH
and IZB mbH by Life Science CLUSTERS magazine
avakado Ltd Global House 13 Market Square Horsham
West Sussex RH12 1EU United Kingdom
Tel: +44 (0)1403 220760 Fax: +44 (0)1403 220761
© avakado Ltd 2009
T
he Greater Munich Biotech
Region boasts nearly 400 life
science companies and eight
renowned research institutions.
Producing a turnover of €10.5 billion in
2008 and employing over 30,000 people
in industry and research, the sector is
making a major contribution to the
economic power of Greater Munich and
has seen the rise of a well developed
cluster in and around the city.
A wide variety of life science
companies and research institutions
work in the Greater Munich Biotech
Region. 127 small and mid-size biotech
companies are joined by 78 international
companies working in biotechnology
and pharmaceuticals. In addition, there
are 53 contract research organisations
and 127 other life science companies, as
well as suppliers and wholesalers.
Solid foundations to
critical mass
The story started in the early 70s with the
establishment of the university clinic in
Großhadern on the southwestern
outskirts of Munich. The mid 70s saw the
foundation of the Max Planck Institute for
Biochemistry in Martinsried near Munich,
followed in the mid 80s by the German
Gene Centre, also located in Martinsried.
These two institutions laid the solid
cornerstone for research in the region,
and enjoy international renown today.
It only took a few years before the
‘critical mass’ of application-oriented
scientists was available to generate a
strong dynamic, leading to the
foundation in the late 80s and early 90s
of companies such as Mikrogen,
Micromet, MorphoSys and MediGene.
The development in Martinsried was
boosted still further from 1995 after the
foundation of the Innovation Centre for
Biotechnology (IZB), the centre in the
region specifically geared to
biotechnology, where most of the firms
presented in this publication started their
careers. The spirit of optimism got yet
another boost when the region
participated successfully in the ’BioRegio’
competition organised by the German
Federal Ministry of Education and
Research in 1996. This resulted in a real
start-up boom in 1997 and 1998, which
generated over 150 new biotech
companies. Today the Greater Munich
Biotech Region is Germany‘s leading
centre for ‘red biotechnology’, in a
compact and easily accessible location
with short distances between campuses
and institutions.
In contrast to biotechnology, many
pharmaceutical companies have been
based in the Region for decades. Most of
them are small to midsize but there are
also international Big Pharma companies
that have come to Munich specifically to
create centres of research, production or
marketing for Central Europe. First of all
it was Roche from Switzerland that
found itself in the lovely environment of
Penzberg, near the Bavarian Alps, after
acquisition of Boehringer Mannheim.
This was of course not just for the
scenery: Roche invested more than €1.5
billion in the Penzberg location, doubling
the employees in only ten years to more
than 4500, generating a world leading
research and production plant.
GlaxoSmithKline carries out a major
portion of its clinical trials in Munich.
General Electric Healthcare (GEHC)
All the ingredients
for life science
excellence
Since the 1990s Munich and the surrounding Greater
Munich Biotech Region have developed into a leading
business centre for the life science industries. Today it can
justly claim to rank in the top four biotechnology
locations in Europe. Life Science Clusters magazine Editor,
Brian Cooper, explores what it has taken to create this
recipe for success.
4
Greater Munich Biotech Region
Editorial
opened its new international R&D
centre, the GE Global Research
Centre, in Garching near Munich in
2004. Merck & Co decided in 2007
to move its EMEAC-hub (Europe,
Middle East, Africa, Canada) to Haar,
near Munich. When two Japanese
pharmaceutical companies, one of
which had taken over the Luitpold
works (Mobilat) in Pfaffenhofen,
merged to form Daiichi-Sankyo, the
new Japanese conglomerate found
itself firmly established in the Region.
And this commitment was extended
in 2008 when Daiichi-Sankyo took
over the Martinsried company U3
Pharma to build upon its strong
scientific pipeline, which is connected
with the name of Prof Dr Axel Ullrich.
Excellence in research
An important factor that attracts
business activities and encourages
company growth in biotechnology,
pharmaceuticals and the entire life
sciences is the availability of sufficient
qualified staff at the chosen location.
The greater metropolitan region of
Munich, with its universities and
extra-mural research institutions, is
very privileged in this regard.
Aside from the respective
departments at the Ludwig-
Maximilians-Universität (LMU Munich)
and the Technische Universität
München (TUM) – both universities
designated Excellence Universities by
the Federal Government – there are
the three Max Planck Institutes
(Neurobiology, Biochemistry and
Psychiatry) devoted to biology and
biomedicine, the Helmholtz Zentrum
Munich – German Research Centre
for Environmental Health
(Neuherberg), as well as the
universities of applied science in
Munich and Weihenstephan.
Research done at these centres is as
broad as the life sciences themselves.
It ranges from cellular and molecular
biology and chemistry to
nanotechnology, from oncology,
cardiovascular and central nervous
system diseases to infectious diseases,
from interdisciplinary research to
highly specialised areas of study.
The LMU has moved all its natural
science institutes to the southwest of
Munich (Martinsried-Großhadern),
the Departments of Biology,
Chemistry and Pharmaceutics
complementing the established Max
Planck Institutes for Biochemistry and
for Neurobiology to form a strong
molecular and cell biological pillar
there. The idea of a research campus
in Großhadern/Martinsried is
becoming a reality – and will be
complemented in coming years by a
biomedical research centre.
The TUM, on the other hand, has
chosen to make the north of Munich
its centre of research, moving many
departments to Garching and closely
linking the historical origins of
biotechnology represented by beer
brewing, with the most modern
approaches to research in molecular
structural analysis in the Centre of
Life and Food Sciences
Weihenstephan. All research in food
and agricultural science is now
located in Weihenstephan, with a
wide variety of reciprocal links to
health and environmental science –
be it with the TUM Department of
Medicine or with the German
Research Centre for Environmental
Health also situated in the north of
Munich. Many government agencies
responsible for the life sciences are
also located in the north of Munich
or in Weihenstephan and complete
the strong bioscience pillar in the
north of the Region.
Support network
The Greater Munich Biotech Region
has several new business centres
which provide a key role in
technology transfer, and is expanding
existing capacities. Created and
designed especially for biotechnology,
the two Innovation Centres for
Biotechnology belonging to the IZB in
Martinsried and Weihenstephan play
a special role in the start-up scene –
with additional services in consultancy
and financing provided by the
support association Bio
M
. A
considerable number of companies
that share close networking ties have
sprung up around biotechnology and
pharmaceuticals, including suppliers,
commercial enterprises and other
services. Of particular note is the large
number of more than 50 contract
research organisations. Many other
consultants, from patent attorneys to
marketing specialists for the life
science sector, or specialists in lab
equipment complete the range of job
fields connected to biotechnology
and pharmaceuticals.
5
Academic collaboration
Greater Munich Biotech Region
P
rof Dr Axel Ullrich has a
career which spans both
academic research and
successful commercial drug
development.
Since 1988 Prof Dr Axel Ullrich
has been Director of the
Department of Molecular Biology
at the Max Planck Institute for
Biochemistry in Martinsried at
Munich. As an academic and
applied research scientist, his work
includes more than 500 scientific
publications and more than 80,000
citations, making him one of the
10 most cited scientists of the last
25 years and a pioneer of
Molecular Medicine. In the early
days of Gene Technology research
Ullrich cloned the first medically-
relevant gene – insulin – which led
to Humulin for Diabetics and
subsequently several cell surface
growth factor receptors which
opened up applications for
targeted cancer therapy
development. He laid the scientific
groundwork for the humanised
anti-HER2 antibody Trastuzumab
(Herceptin
®
) and the multi-targeted
kinase blocker Sunitinib (Sutent
®
'),
both anticancer drugs.
For his work and discoveries in the
field of molecular signal transduction
of cell and tumour biology he has
been honoured with numerous
awards:
• 1987: Paul Langerhans Medal of
the German Diabetes Society
• 1998: German Cancer Award of
the German Cancer Society, jointly
with Harald Stein
• 2000: Bruce F Cain Memorial
Award of the American Association
for Cancer Research
• 2001: Robert Koch Prize
• 2003: King Faisal International
Prize of Medicine
• 2007: Warren Alpert Prize of
Harvard Medical School
• 2007: Prince Mahidol Award of
Medicine, Thailand
• 2007: Karlheinz Beckurts Prize
• 2009: presenter of the Emanuel
Merck Lecture
• 2009: Dr Paul Janssen Award for
Biomedical Research, Johnson &
Johnson
Prof Ullrich is an elected member of
the European Molecular Biology
Organisation (EMBO), the German
Academy of Sciences Leopoldina and
American Academy of Arts and
Sciences.
Making the transition
to industry
Prof Ullrich studied biochemistry as
an undergraduate at the University
of Tübingen. After graduating, he
moved to the University of
Heidelberg until 1975, when he
went to the Department of
Biochemistry and Biophysics of the
University of California as
postdoctoral fellow. From 1979 he
worked at the then recently
founded biotech company,
Genentech, until he returned to
Germany in 1988.
In addition to his academic work,
Prof Ullrich has to date been a
founder of four biotech companies:
- Sugen, established in 1991 in
California, now part of Pfizer;
- Axxima Pharmaceuticals, founded
in 1998 in Martinsried;
- U3 Pharma, founded in 2001 and
also located in Martinsried, acquired
by Daiichi-Sankyo in 2008;
- Kinaxo, set up in 2005 in
Martinsried.
Prof Ullrich is Honorary Professor
of the Second Military Medical
University in Shanghai and the
University of Tübingen. Since 2004
he has been Founder and Director
of the Singapore Onco Genome
Laboratory, a cooperation of Max-
Planck-Gesellschaft and the
Agency for Science, Technology
and Research (A*STAR) in
Singapore.
LSC:You were at the core of a most
exciting biotech development
period in California. How does the
present atmosphere in Martinsried
compare?
Ullrich:While the biotech industry
was still in its infancy in 1978-1985,
it has grown up now worldwide
including Martinsried Valley.
LSC: Three of the start-up
companies with which you had
been involved since their founding
have since been acquired by big
pharma. This has been a typical
model; is it still an efficient and
effective way to bring research to
market?
Ullrich:It was very effective and
beneficial for both sides. The
situation is largely different now as
a consequence of a drastic change
in the financing culture.
LSC:Is there sufficient co-operation
between research institutes and bio-
clusters both nationally and
internationally to ensure that
development work is not being
duplicated, and that innovative
programmes are working together
to achieve common aims?
Ullrich: There is never enough co-
operation but in a competitive
environment this is difficult to
achieve.
LSC:What is your prognosis for the
diagnosis and treatment of cancer
in the future?
Ullrich:There will be better and
better oncogenomics-based
diagnostic methods which will allow
the implementation of individual
therapeutic strategies involving a
growing armamentarium of
therapeutic agents. Whether this
will lead to cures and when is not
predictable.
LSC:Can academics make the
transition to CEOs (or indeed do
they want to!)?
Ullrich: This question can only be
answered on an individual basis.
Everything is possible!
Combining research and business
in drug discovery
Prof Dr Axel Ullrich, Director of
the Department of Molecular
Biology at the Max Planck
Institute for Biochemistry in
Martinsried
Life Science Clusters asked Prof Ullrich to sum up the cluster environment in the
Greater Munich Biotech Region.
6
Greater Munich Biotech Region
Bavarian biotechs move from
adaptation via selection to
survival of the fittest
In just twenty years biotechnology has evolved in Bavaria from some crazy ideas to tested and
approved products, and the pipeline continues to produce innovations and solutions.
Prof Dr Horst Domdey, president of the regional support association Bio
M
, traces the Darwinian
process which has resulted in, arguably, Germany’s most successful biocluster.
E
volution by Innovation is the
slogan we have selected for
our Annual Report of the
Bavarian Biotechnology
Industry– in which the Greater
Munich Area represents about 80%
of Bavaria as a whole. This title is, of
course, intended to be a tribute to
Charles Darwin who is celebrated
this year for at least two reasons:
2009 is the 200th anniversary of
Charles Darwin’s birthday and it is
also the 150th anniversary of the
first publication of his famous book
On the Origin of Species, which
marks the beginning of the
evolutionary theory. And the link to
this evolutionary theme is not too
far-fetched.
It is just twenty years since the
evolutionary process – the creation of
innovative and marketable products
starting from ‘crazy ideas’ – began in
Bavaria´s biotechnology sector; from
the time when the first companies of
this type were created and
established in Martinsried near
Munich. In the past twenty years, the
creation, occupation and defence of a
new niche in the healthcare market –
what most of the Bavarian companies
are aiming for – has passed through
all the chapters in On the Origin of
Species, from adaptation via selection
to survival of the fittest.
Let´s look at the status of the
Greater Munich Biotech Region,
where the main focus is on ‘Health’.
The biotech industry here is
distinguished by a strong focus on ‘red
biotechnology’, biotechnology related
to human or veterinary medicine (Fig
1). Seventy companies, or almost half
(47%) of all surveyed ‘core biotech
companies’ work in the area of drug
and diagnostics development.
Dynamic founders
As mentioned in the Editorial, the vast
majority of companies were founded
in the mid Nineties of the last century
with the highest numbers around
1998-2000. After that - you will
remember the Internet-Doom at the
stock exchanges which also
collaterally hit the biotechs - only few
companies (and founders) made their
way to market. But this picture
changes in the last few years: In the
past three years, 24 biotech
companies have been founded; 2008
alone saw 14 companies starting up
(Fig 2). Twelve of these are spin-offs
from universities or research
institutions and nine were hived off
from companies. Most of these start-
ups in the past few years have been
biotechnology service providers
offering a very wide range of highly
specialised technical services. We
have learned with companies like
MorphoSys that a strong technology
platform can be the best basis from
which to evolve into a drug
developing company. Drug
development alone has only rarely
been the immediate incentive to set
up a new business; this is doubtless
connected to the difficulties
involved in securing financing for
such companies.
New financing models
This leads us to the topic of financing
in general. The issue of financing
concerns companies in the biotech
industry to various degrees.
Companies with marketable products
and services are generally relatively
independent of external financing.
But companies needing long lead
times to develop products to bring
them to market can hardly survive
without external financing. This is
particularly true for companies in
drug research, which are strongly
represented in the Greater Munich
Area. Several of these companies are
listed on the stockmarket and are
financed through the capital market.
Representation
48%
26%
14%
7%
5%
Therapeutic agents and diagnostics
Instruments and reagents
Biotech services
Agriculture, food, environment
Bioinformatics
Fig 1. The biotech industry in the Greater Munich Biotech Region is distinguished by a strong focus on ‘red biotechnology’.
7
The volume of finance since the
beginnings of biotechnology over
ten years ago has varied
considerably. The first major peak
was based on the euphoria of the
‘new market economy’, which led
to an equally dramatic drop around
the year 2000. 2005 and 2006
again yielded somewhat higher
volumes of investment, but since
then the Munich Region and the
whole of Germany have seen a
decline in this type of financing. In
2007 financial investments in our
region amounted to about €150M,
and in 2008 they were down to
about €100M.
But, to come back to Charles
Darwin, changing (financial)
environment needs adaptation.
Several biotechnology SMEs have in
the meantime been able to procure
long term financial commitments
independent of the stockmarket
through co-operations with other
companies (for example the
cooperation of MorphoSys with
Novartis worth up to $1bn!). Two
companies were able to negotiate a
new type of ‘financing on demand’
by international investors in 2008:
Micromet was promised the use of
€59M “if required”, and MediGene
was promised €25M. And only few
weeks ago, Micromet raised over
€70M by increasing its capital stock -
and all this in a surrounding of
financial crisis!
Product pipeline
In Germany a total of five
compounds produced by core
biotech companies have been
licensed so far, four in Munich and
one in Berlin. This puts Munich
companies in the lead in Germany.
Eligard, an agent to cure prostate
cancer, was licensed by MediGene
in 2003, making it the first
German biotech company to be
awarded such a licence. In the
meantime MediGene has gone on
to receive two further
international licences for
compounds, making it the
champion in drug
development among
biotechnology SMEs in Germany.
In spring of 2009 two Munich-
based companies, Fresenius
Biotech and its development
partner Trion Pharma, were
approved by the European
Medicines Agency (EMEA) for a
innovative compound; this is a
‘trifunctional’ antibody against
malignant ascites (now being
tested for other indications),
invented over a decade ago at the
Munich Helmholtz Zentrum.
In the area of human medicine
269 diagnostics products from
Munich companies are already on
the market, one new product is at
the end of the licensing process,
and 22 products are in various
stages of development.
Representation
Greater Munich Biotech Region
Cluster management
Bio
M
Biotech Cluster Development GmbH, located in Martinsried, is a service and consulting company aiming to promote the
development of the Munich Biotech Cluster as an internationally renowned centre of excellence in the field of innovative
biotechnology. It is the first point of contact for biotech start-up companies seeking financial support or business advice. National and
international investors also contact Bio
M
for guidance to the most interesting technologies or companies. Bio
M
assists Munich-based
companies in finding the right contacts and partners through its network, which includes all important players in the region:
representatives from public offices, scientific institutions, venture capitalists and biotech companies.
Bio
M
activities for the Biotech Cluster are consulting and information services, networking activities, PR and marketing work.
Bio
M
also organises seminars and workshops on a broad range of topics relevant to the successful development of a biotech company. Young firms are
offered the possibility of participating in larger exhibitions, partnering events, scientific conferences and other relevant events. Bio
M
operates an informative
website with an on-line job market and it publishes a monthly newsletter with information from the local Biotechnology and Life Science sector.
Thanks to the excellence in science and the supporting environment (of which the incubator IZB is a key to our success story) more than 100 companies
have managed the ‘struggle of economic life’ and helped us to build up a renowned Munich Biotech Cluster.
www.bio-m.org
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
34 19 19 13 13 9 10 5 9 10 3 7 14
before
1997
40
35
30
25
20
15
10
5
0
number of biotech start-ups
Fig 2. In the past three years, 24 biotech companies have been founded, and 2008 alone saw
14 companies starting up.
Prof Dr Horst
Domdey is the
President of
Bio
M
AG and
Managing
Director of
Bio
M
Biotech
Cluster
Development
GmbH,
Martinsried, as well as
Spokesman of Cluster
Biotechnologie Bayern, part of
the Bavarian Cluster initiative of
the Bavarian State Government.
He is a member of the
research committee of the DIHT
and Scientific Director of the
Bavarian genome research
network Bay Gene. Since 1998
he has been teaching as an
Honorary Professor for
Biochemistry at LMU Munich.
8
Greater Munich Biotech Region
Incubator
IZB - an ideal incubator for
biotech start-ups
Since its establishment in 1995 some 100 life-science firms have been founded under the roof of
the IZB, and former IZB tenants have created more than 1000 permanent jobs. The incubator has
been the birthplace for several world renowned companies.
L
ife sciences are among the key
technologies of the future.
They will provide new
medicines and treatments
against cancer and other diseases,
but they will also be the key to
innovation in environmental, food
and agricultural technology. In 1994
Bavaria’s Ministry of Economic Affairs
realised the potential for medical
biotechnology and life sciences in
and around Martinsried near Munich,
and initiated the creation of a top
biotechnology location.
Following the Großhadern
university hospital, the Gene Centre
of the Ludwig-Maximilians University
(LMU) and the Max Planck Institutes
of Biochemistry and Neurobiology,
the chairs of Chemistry, Pharmacy
and Biology as well as the pre-
clinical institutes of the Medical
Faculty of LMU were relocated in
Martinsried as a logical next step. In
the near future, the LMU is planning
to establish the Biomedical Centre
and a dementia research centre.
In addition to being close to a
motorway junction and served by
many bus routes,
the campus will be connected to the
subway by 2013. The achievements
that have been realised in
Martinsried in little more than ten
years are enormous.
A few years ago, the IZB extended
to the north, with a Centre of Life
and Food Sciences being developed in
Freising-Weihenstephan, close to the
Science Centre of Munich’s Technical
University (TU) and the Munich Franz
Josef Strauß international airport.
Where the future
becomes reality
The Innovation and Start-up Centre
for Biotechnology (IZB), at the heart
of this outstanding campus, provides
newly established companies with
optimal working conditions.
Currently close to 600 people are
employed by 60 firms at the IZB.
Innovative medicines developed by
IZB companies are already on the
market with many others in the
pipeline. Thirty drug candidates are
currently being tested internationally;
70 agents are undergoing
clinical trials.
Besides fully equipped BSL-1 and BSL-
2 laboratories, the IZB offers
researchers the technology that is
needed to work efficiently: fast data
connections, modern conference
rooms – also available to external
companies – and proactive public
relation support. Proximity to
scientific institutions facilitates rapid
exchange of experience. With the
motto ‘Where the future becomes
reality’, the Start-up Centre has made
an international name for itself.
From acorns to oaks
In 2008, IZB tenants raised more
than €80M in fresh capital. Due to
the high occupancy level of the
existing 19,000 sq m, planning for
another office/laboratory building of
3200 sq m started in 2009, and is to
be completed in mid-2010. As a
novel feature, it will include a school
for technical assistants.
Fördergesellschaft IZB mbH (IZB
GmbH) was one of the first not-for-
profit private enterprise organisations
in Bavaria, and has been led by
managing director Dr Peter Hanns
Zobel since 1996.
World renowned companies that
started from here:
MediGene, Morphosys, Metabion,
Micromet and MediGenomix all
attest to the excellent performance
of the start-up centre.
It is important that IZB mbH
employees are easily available to
support IZB entrepreneurs. Fourteen
years of experience with start-up
companies and an efficient network
assure that the organisation can also
solve “your” problem. The
Freshmaker café and the bioKids
daycare centre both add to the
convenience of being located at IZB.
Tenant companies are reassured
by the constant presence of IZB
personnel and the certainty of
knowing that its activities are
supported ‘from above’: Both the
Bavarian Ministry of Economic Affairs
and the main shareholder, the
Bavarian Ministry of Finance, have
been continuously supportive ever
since the IZB was established.
The two excellence universities,
the outstanding research of the Max
Planck Institutes and the institutes of
TU and LMU, and also the 100
young biotech businesses are a
guarantee of the ongoing
development of the Metropolitan
Region of Munich.
Contact:
Fördergesellschaft IZB mbH,
Dr Peter Hanns Zobel,
Am Klopferspitz 19,
82152 Martinsried, Germany.
www.izb-online.de
9
Pharmaceuticals
Greater Munich Biotech Region
In 2008 GSK established the following three strategic priorities: grow a diversified global business;
deliver more products of value; simplify the operating model. The company believes these
priorities will enable it to navigate the coming years successfully and retain its position as a
company able to meet patients’ and healthcare providers’ needs into the future.
G
laxoSmithKline – one of
the world’s leading
research-based
pharmaceutical and
healthcare companies – is
committed to improving the quality
of human life by enabling people to
do more, feel better and live longer.
Headquartered in the UK and with
operations based in the US, GSK has
an estimated seven per cent of the
world's pharmaceutical market and
employs around 99,000 people
worldwide in over 100 countries. The
company produces medicines that
treat six major disease areas –
asthma, virus control, infections,
mental health, diabetes and digestive
conditions - and is developing new
treatments for cancer. In addition, it
is a leader in the important area of
vaccines. GSK is one of the few
pharmaceutical companies
researching both medicines and
vaccines for the World Health
Organization’s three priority diseases
– HIV/AIDS, tuberculosis and malaria.
Heavy R&D commitment
In 2008, GSK invested
approximately €5 billion in R&D.
Currently the company is running
more than 150 clinical
development projects with more
than 30 products in late-stage
development. GSK’s products are
marketed in more than 150
countries. Five scientists have
received the Nobel Prize for their
R&D associated with
GlaxoSmithKline’s preparations.
In Germany, GlaxoSmithKline is
represented with the business units
Pharmaceuticals located in Munich
and Consumer Healthcare located
in Buehl, employing more than
3000 people and creating a
turnover of more than €1.3 billion
in Germany in 2008. Since 1992,
the Dresden site, as a member of
the international corporate division
GlaxoSmithKline Biologicals, has
been the European centre for the
development and production of
influenza vaccines - including the
production of the pandemic
vaccine against the “novel flu”.
Influenza vaccines from Dresden
are marketed worldwide in about
70 countries.
GSK is committed to the
responsible management of ethical,
social and environmental concerns
and, in particular, to playing a
leading role in supporting
healthcare in the developing world.
www.glaxosmithkline.de
Do more, feel better,
live longer
Research is the engine: GSK is a research-based company.
GSK headquarters in Munich.
10
Greater Munich Biotech Region
Drug Discovery
Antibodies and small molecules for targeted
cancer treatment
With two substances in Phase III registration trials, WILEX aims to be able to
finance its R&D programmes from operating cash flow within a few years.
W
ILEX AG is a
biopharmaceutical
company based in
Munich and is listed on the
Frankfurt Stock Exchange. It was
founded in 1997 by a team of
physicians and oncologists from the
Technical University of Munich.
WILEX’s mission is to develop drugs
with a low side effect profile and
targeted treatment of different
types of cancer as well as
diagnostic agents for specific
detection of tumours. The
company's product candidates are
based on antibodies and small
molecules. The substances
RENCAREX
®
and REDECTANE
®
are
currently undergoing Phase III
registration trials. The uPA inhibitor
MESUPRON
®
is in Phase II trials
in two indications. For the MEK-
inhibitor WX-554 an application
for approval of Phase I trial has
been filed, and for the PI3K
inhibitor WX-037, a lead compound
has been selected. WILEX expects
multiple inflection points in the
next months with data from two
product candidates and other
important milestones.
Strong partner
In 2009 UCB and WILEX entered
into a strategic alliance to develop
UCB’s pre-clinical oncology
portfolio. In 2008, WILEX signed a
worldwide marketing, distribution
and sales agreement on
REDECTANE
®
with Ion Beam
Applications. In 2004, WILEX
began a co-development and
commercialisation agreement for
RENCAREX
®
with Laboratorios del
Dr Esteve in certain countries in
Southern Europe. WILEX plans to
further commercialise its products
through partnerships.
www.wilex.com
StatusName
Development
status
Indication
Fully enrolled (864 pt), Positive interim analysis
for futility after 100 events,
Next: 343 events triggers data point
RENCAREX
®
(antibody)
Phase III
Non met. clear
cell renal cell
cancer
SPA from FDA, enrolment completed (225 pt),
Next: Data (Q4/2009)
REDECTANE
®
(antibody for
diagnostic use)
Phase III
Renal mass
Patient enrolment ongoing
(target 114 pt)
MESUPRON
®
(uPA inhibitor)
Phase II
Breast
cancer
Fully enrolled (95 pt)
Next: Data (Q4/2009)
MESUPRON
®
(uPA inhibitor)
Phase II
Pancreas
cancer
IMPD submitted (triggers EUR 5m)
Next: Start trial (Q4/2009; triggers
further EUR 5m)
WX-554
(MEK inhibitor)*
Phase I in prep.
Cancer
Lead compound selected
WX-037
(PI3K inhibitor)*
Pre-clinical
Cancer
Research
3 Antibody
programmes*
Pre-clinical
Cancer
*acquired from UCB
First German biotech company to bring
developed drug to market
MediGene pursues integration of all the core areas of a modern biopharmaceuticals
company from research to drug development and commercialisation.
M
ediGene concentrates on
researching, developing,
and commercialising novel
drugs in two therapeutic areas -
cancer and autoimmune diseases,
and is the first German biotech
company to have drugs on the
market. Until now, its drugs have
been distributed by partner
companies. MediGene has several
drug candidates in clinical
development. In addition, it possesses
innovative platform technologies
which enable the search for other
therapeutic substances. Licensed
products complement the proprietary
drug portfolio. This allows the
company to reduce risks, enhance
opportunities, and accelerate revenue
generation. In early 2009 MediGene
shares were listed on the TechDAX
index and Dr Frank Mathias was
appointed Chief Executive Officer of
MediGene AG.
Pipeline
In May 2009 MediGene obtained
orphan drug designation for
EndoTAGTM-1 by the US regulatory
authority. This followed the October
2008 presentation of results
obtained in a clinical phase II trial of
the drug candidate EndoTAGTM-1
for the treatment of pancreatic
carcinoma. Since April 2007, phase II
trials have been conducted on
EndoTAGTM-1 for the treatment of
triple receptor-negative breast
cancer. Patient recruitment is to be
completed in 2009, and final
evaluation of the trial is expected
for the first six months of 2010.
At the beginning of 2009
MediGene announced the start of
sales promotion and active
marketing of Veregen
®
in the USA
through its partner Nycomed. A
marketing partnership agreement
was concluded for commercialisation
of Veregen
®
in Spain and Portugal,
and recently the Marketing
Authorisation Application for
Veregen
®
was assessed positively by
the national regulatory authorities of
the first European countries.
MediGene is planning
commercialisation of Veregen
®
in
Germany and other European
countries via distribution partners, and
is in negotiations for the conclusion of
a global partnership for EndoTAGTM-1.
MediGenes activities are
supported by the benefits of the
Greater Munich Biotech Region,
which offers network-platforms and
services tailored to particular needs
of its business area.
www.medigene.com
Dr Frank Mathias was appointed
MediGene CEO at the company’s
listing on the Tech DAX index.
Exposing cancer to the power of immune response
The trifunctional antibody Removab
®
(catumaxomab) obtained EMEA approval
in spring of this year for the intraperitoneal treatment of malignant ascites.
T
RION Pharma is a privately held
biopharmaceutical company
that has established a novel
approach to cancer immunotherapy.
The company’s unique family of
trifunctional antibodies, called
Triomab
®
, simultaneously activates
multiple immune defence mechanisms
against cancer. As a result, tumour
cells are specifically destroyed with
hitherto unknown potency and
precision. Moreover, the patient’s
immune system seems to emerge
from Triomab
®
treatment with
improved, long-term cancer immunity
– an effect that can otherwise only be
achieved through vaccination.
More than ten years ago, Dr Horst
Lindhofer, working at the Helmholtz
Zentrum Munich located in the
northern part of the city, made a
striking discovery: By modifying an
antibody to present three different
binding sites instead of two, the
antibody is able to retarget the most
potent killer cell of the human
immune-system – the T-cell – as well
as accessory cells toward the tumour.
To further investigate these findings
TRION Pharma was spun out of the
extra-faculty research institute.
At the same time, Lindhofer founded
a sister company, TRION Research, to
focus on the generation of new
Triomab
®
candidates and clinical
analytics, while TRION Pharma
manages process development and
in-house GMP manufacturing, and is
actively involved in clinical development.
From research to market
Back then, like today, the entire
Munich Biotech Cluster promoted a
strong entrepreneurial spirit – an
attractive environment for industrial
partners. TRION was able to profit
from this striving environment by
partnering with the medical care
company Fresenius, leading to a very
strong strategic alliance. Within this
partnership, Fresenius took
responsibility for the clinical
approval process and sales and
marketing. A few years later both
companies finally succeeded. In April
2009, the European Commission
gave the go-ahead after the EMEA
recommended approval of the
antibody Removab
®
(catumaxomab)
for the intraperitoneal treatment of
malignant ascites in patients with
EpCAM-positve carcinoms. Now the
first ‘trifunctional’ antibody, at the
same time being the first drug
addressing malignant ascites as well
as the first entire ‘Munich’
biotech-drug is available to patients.
The latest approved drug is a
perfect example of how the Munich
Biotech Cluster provides a framework
for entrepreneurial spirit and success.
www.trionpharma.com
Trifunctional antibody: by modifying an antibody to present three
different binding sites instead of two, it is able to retarget the most potent
killer cell of the human immune-system.
Drug Discovery
Bringing effective antibody therapies to patients
11
Greater Munich Biotech Region
F
resenius Biotech GmbH is a
globally operating company
dedicated to delivering targeted
biopharmaceutical treatment
options to patients with serious
illnesses. A focal point of activity is
the development of
immunotherapeutic products based
on innovative antibody technologies.
Oncology
The trifunctional antibody Removab
®
(catumaxomab) represents a new
generation of antibodies. The antibody
was discovered and is produced by
TRION Pharma. Early in the process
Fresenius Biotech recognised the
potential of this promising candidate
and initiated an extensive clinical
development programme. Within only
eight years Fresenius brought the
product from its first use in clinical
trials, through the entire regulatory
approval process to European-wide
marketing approval. Since April 2009
Fresenius Biotech has held the EU
marketing authorisation for
Removab
®
,the first drug approved
for the treatment of malignant ascites
in patients with EpCAM positive
carcinomas. Fresenius Biotech is a
shareholder of TRION Pharma.
Fresenius Biotech has
launched Removab
®
in
Germany and Austria
and will subsequently
introduce the
product in other
European markets.
Commercialisation is
managed through the Fresenius
Biotech headquarters in Munich,
supported by further locations in
France, Italy and Spain.
Transplantation
For more than 25 years Fresenius
Biotech has been successfully
marketing ATG-Fresenius S, a
polyclonal antibody for the treatment
and prevention of acute transplant
rejection after solid organ
transplantation. The
immunosuppressive potential of ATG-
Fresenius S in additional indications
and other disease areas is being
further explored in extended clinical
development programmes. ATG-
Fresenius S has proved effectiveness
in prevention of graft-versus-host
disease after stem cell
transplantation.
The production facilities for ATG-
Fresenius S are located in the south
of Munich embedded in the
infrastructure of the Greater Munich
Biotech Region.
Fresenius Biotech GmbH has a long
tradition in the network of the Greater
Munich Biotech Region. ATG-Fresenius
S was developed in cooperation with
Prof H V Rodt at GSF, now part of the
Helmholtz Zentrum Munich. About 20
years later another successful
cooperation was started with Dr H
Lindhofer, Helmholtz Zentrum
Munich, founder of TRION Pharma.
www.fresenius-biotech.com
Fresenius Biotech focuses on the development and marketing of
biopharmaceuticals in the fields of oncology and transplantation medicine.
Catumaxomab (Removab
®
) passed
an efficient clinical development
and approval programme under the
responsibility of Fresenius Biotech.
12
Greater Munich Biotech Region
Drug Discovery
Targeted therapeutics derived
from human lipocalins
Engineering of novel proteins, for development as therapeutic
and diagnostic products, is well advanced at Pieris AG.
P
ieris AG is a biopharmaceutical
company engaged in the
discovery and development of
Anticalins
®
, a novel class of targeted
protein therapeutics, for the
diagnosis and treatment of severe
human disorders.
The company was established in
2001 with the vision of
commercially exploiting
technologies developed originally by
Prof Dr Arne Skerra, Head of the
Department of Biological Chemistry
at the Technical University of
Munich (TUM). While the scientific
excellence of Prof Dr Skerra and his
fellow Pieris co-founders has long
been recognised by the academic
community, the product
commercialisation potential of their
discoveries was acknowledged
through Pieris’ attainment in 2000
of the first prize in the Munich
Business Plan Contest.
Based in facilities located at
Freising-Weihenstephan, close to
the TUM just north of Munich, Pieris
has now grown to over 35
employees with considerable
experience and know-how in the
engineering of novel proteins for
development as diagnostic and
therapeutic products.
Mini antibodies
The basis of the company is
research work in the field of
lipocalins. These proteins bind
small molecules and also have a
transporting function. They can be
modified so that they can bind any
desired target. They are only a
seventh of the size of monoclonal
antibodies, which represents a
substantial advantage. They can
thus, for example, reach the
bloodstream via the lungs and are
therefore suitable for inhalers.
In summer, the company
reported that Wacker Biotech
GmbH, has confirmed the
scalability of the Anticalins and
will take over production of the
active substance.
Progress report for PRS-050
In spring of this year Pieris reported
that it has made significant progress
in the development of its Anticalin
candidate PRS-050, a potent VEGF
antagonist with broad therapeutic
applicability. Having successfully
demonstrated the mode of action of
PRS-050 in vitro and in vivo, Pieris
has now validated the efficacy of
the product candidate in several
preclinical models. Production
process parameters for GMP
manufacture of PRS-050 have also
been clearly defined. Initial
toxicology results have shown that
PRS-050 is very well tolerated.
www.pieris-ag.com
Pieris has now validated the efficacy of its Anticalin candidate PRS-050
in several preclinical models.
Pieris collaborates with Allergan Inc
In September Pieris announced that it has entered into a collaboration agreement with Allergan Inc, headquartered in California, that combines Pieris’
proprietary Anticalin technology with Allergan’s expertise in drug delivery and ophthalmic drug development, with a goal of developing agents for the
treatment of serious ocular disorders.
Under the terms of the collaboration Pieris will work with Allergan to optimise existing lead Anticalins and to design novel Anticalins. Allergan will be
solely responsible for all discovery, development, and commercialisation costs and will be responsible for clinical development and related activities and
commercialisation. Pieris has granted Allergan a worldwide and exclusive license to Allergan for specific Anticalins to be used in the field and in return will
receive an upfront payment of $10M.
“Allergan has world class expertise in ophthalmology, and we look forward to working together to develop Anticalins as important medicines for
the treatment of a number of ocular diseases. This collaboration further validates the potential for Anticalins as a new drug-class”, said Claus
Schalper, Interim CEO of Pieris.
Based in facilities located at Freising-Weihenstephan, close to the TUM
just north of Munich, Pieris has grown to over 35 employees.
13
Drug Discovery
Greater Munich Biotech Region
Novel antibody-based drugs for treatment of
cancer, inflammation and autoimmune diseases
Micromet is a biotechnology company focusing on the research and development of antibodies generated
with its proprietary BiTE antibody platform, as well as conventional monoclonal antibodies.
Fighting disease is a complicated job. But Emergent Biosolutions’s mission
remains stunningly simple: to protect life.
U
sing its antibody technology
platforms, Micromet aims to
create drugs that are specific,
effective and well tolerated in patients.
In cancer, these drugs precisely target
and destroy tumour cells. In the case
of inflammatory and autoimmune
diseases, they either trap key signalling
molecules or eliminate subpopulations
of immune cells that cause acute and
chronic inflammation.
Micromet AG was founded in
1993 as a spin-off from the Institute
for Immunology, Munich University,
Germany. In May 2006, Micromet AG
merged with CancerVax Corporation
to form Micromet Inc, headquartered
in Bethesda, MD, USA.
Drug candidates in phase 1
and phase 2 trials
Micromet’s product development
pipeline includes novel antibodies
generated with its proprietary BiTE
antibody platform, as well as
conventional monoclonal antibodies.
BiTE antibodies represent a new class
of antibodies that activate the T cells
of a patient's immune system to
eliminate cancer cells. Five of
Micromet's antibodies are currently
in clinical trials. Its BiTE antibody
blinatumomab (MT103) is in a phase
2 clinical trial for the treatment of
patients with acute lymphoblastic
leukemia (ALL), and in a phase 1
clinical trial for the treatment of
patients with non-Hodgkin's
lymphoma (NHL). A second BiTE
antibody, MT110, is in a phase 1
clinical trial for the treatment of
patients with solid tumours. MT110
binds to the epithelial cell adhesion
molecule, or EpCAM, which is
overexpressed in many solid tumours.
Micromet's human monoclonal
antibody adecatumumab (MT201)
also binds to EpCAM and is being
developed in collaboration with Merck
Serono. Adecatumumab is in a phase
2 clinical trial in colorectal carcinoma
patients after complete resection of
liver metastases, and a phase 1b
clinical trial evaluating adecatumumab
in combination with docetaxel for the
treatment of patients with metastatic
breast cancer. Micromet's monoclonal
antibody MT293, also known as
TRC093, is licensed to TRACON
Pharmaceuticals, Inc, and is in a phase
1 clinical trial for the treatment of
patients with cancer.
MT203, a human antibody
neutralising the activity of
granulocyte/macrophage colony
stimulating factor (GM-CSF), which
has potential applications in the
treatment of various inflammatory and
autoimmune diseases, such as
rheumatoid arthritis, psoriasis, or
multiple sclerosis, is in a phase 1
clinical trial conducted by Micromet's
collaboration partner Nycomed.
Micromet's licensee Morphotek, a
wholly-owned subsidiary of Eisai, is
also expected to initiate a first phase 1
clinical trial with Micromet's glycolipid-
binding human IgM antibody MT228
for the treatment of melanoma.
Micromet's preclinical product
pipeline includes several novel BiTE
antibodies generated with its
proprietary BiTE antibody platform
technology. A BiTE antibody targeting
CEA for the treatment of solid tumours
is being developed in collaboration
with MedImmune. In addition,
Micromet has entered into an option,
collaboration and license agreement
with Bayer Schering Pharma AG under
which Bayer Schering Pharma was
granted an exclusive option to
license a specified BiTE antibody
against an undisclosed solid tumour
target. Other BiTE antibodies
targeting MSCP, CD33, HER2, EGFR
and other targets are in various
stages of preclinical development.
Public offering
In July Micromet Inc announced the
pricing of its public offering of
14,000,000 shares of common stock
at a public offering price of $5.00 per
share. Micromet also announced in
August that the underwriters for the
offering have exercised in full their
over-allotment option to purchase an
additional 2,100,000 shares, bringing
the total shares sold to 16,100,000
at a price of $5.00 per share for
gross proceeds of $80.5M.
Benefits to Munich
Biotech Region
Micromet has 126 employees in
Munich. The company has grown
over the last several years due to the
advancement of several compounds
into clinical development. Future
growth is likely if these compounds
continue to move through clinical
development.
www.micromet.de
Innovative vaccines and therapeutics that target
infectious diseases
E
mergent BioSolutions Inc is a
biopharmaceutical company
focusing on the development,
manufacture and
commercialisation of vaccines
and therapeutics that assist the
body’s immune system to prevent
or treat disease.
Emergent’s marketed product,
BioThrax (Anthrax Vaccine
Adsorbed), is the only vaccine
licensed by the US Food and Drug
Administration for the prevention
of anthrax. Emergent’s
development pipeline includes
programmes focused on anthrax,
botulism, tuberculosis, typhoid,
hepatitis B and chlamydia.
Through the acquisition of
Martinsried-based Vivacs GmbH in
2006, Emergent BioSolutions –
which already had an existing
sales and marketing presence in
Munich – has added product
development capability to its
German operations. The
acquisition provided Emergent
Biosolutions with access to the
modified vaccinia ankara (MVA)
viral vector MVAtor™ for
injectable vaccines.
www.emergentbiosolutions.com
14
Greater Munich Biotech Region
Towards a better supply of coagulating factors
for haemophilia patients
Development of recombinant pharmaceuticals as a modern alternative to plasma products.
O
ctagene GmbH is a
biotechnological research
company developing
recombinant proteins with a human
cell line as platform technology.
Since being founded in 1997,
experience in the area of research
and development in the field of
human cell lines has developed
extensively, resulting in the
maturation of an effective, product-
oriented biotechnology company.
The emphasis of the company’s work
is the development of recombinant
pharmaceuticals as a modern
alternative to plasma products.
The demand for recombinant
therapies is rising steadily. The
example of the Factor VIII product
(coagulation factor) demonstrates
this especially clearly. The shift of
plasma-derived Factor VIII to
recombinant Factor VIII was reflected
in a clear turnover share increase.
Sales of the recombinant coagulation
factors are continuously growing
with an average double digit rate
since the approval and market
launch of the first recombinant
coagulation factor in 1992.
Human cells for
better compatibility
For the production of proteins with
characteristics identical to those of
humans, Octagene uses human cells,
thus ensuring far better compatibility
with its products for the patients
than that of frequently-used hamster
cell lines. Theoretical research work
is very close to the company’s heart.
As well as being pioneers of
progressive science, Octagene also
hopes to improve the quality of life
for people that are affected and
afflicted with haemophilia with a
half-life prolongation concept.
A human recombinant Factor VIII
produced in a human cell line
developed by Octagene is
manufactured at Octapharma AB in
Sweden and actually running in
clinical phase II. The use of the
human embryonic kidney cell line
HEK293 to produce a Factor VIII
molecule with a human
glycosylation pattern, potentially
resulting in improved function,
reduced product immunogenicity
and reduced allergic reaction as
described for products derived from
hamster cell lines, is the platform
technology of Octagene.
www.octagene.com
SuppreMol specialises in the development of soluble Fcy-receptors which are
recombinant autologous proteins with a proven strong immunosuppressive potential
S
uppreMol GmbH is a privately
held biotechnology company
based in Martinsried that
pioneers a novel approach for the
treatment of autoimmune diseases
which could lead to the cure of these
disorders instead of merely treating
their symptoms. The company is on
the cutting edge of the development
of soluble sFcRs, recombinant versions
of the body’s own proteins, which can
suppress certain reactions of the
immune system very effectively.
Suppremol was founded in 2002
at the Max Planck Institute for
Biochemistry in Martinsried, as a
spin-off of the laboratory of Prof Dr
Robert Huber, the winner of the
Nobel Prize in Chemistry in 1988. It
received its first financing in October
2005 from Z-Cube, a venture capital
company of the Zambon-Pharma
Group in Milan, Italy. In July 2008
SuppreMol closed a significant series
B financing round.
Phase 1 trials near
successful completion
SuppreMol's lead product SM101 is a
recombinant, soluble, non-glycosylated
version of the Fc-receptor γIIb. It binds
to autoantibody/autoantigen
complexes and blocks the triggering of
Fc-receptors on the surface of immune
cells. As a result, the immune response
is downregulated and the activation of
the inflammation cascade typically seen
in autoimmune diseases is prevented.
SuppreMol is using Fcγ receptors
either in a recombinant soluble
version (sFcR) or as targets for an anti-
FcR antibody. The anti-FcR antibody
recruits FcγRIIb for the treatment of
autoimmune diseases that are not
adequately addressed by SM101.
Finally, SuppreMol evaluates in-
licensing opportunities to complement
its current projects in order to further
increase the company’s development
pipeline and intellectual property.
In Spring of this year the company
started a Phase I clinical trial with
SM101. The trial is designed as a
mono-centric, randomised, double-
blind, placebo-controlled study. About
42 male human volunteers between
18 and 40 years received SM101 or
matching placebo intravenously as
single ascending dose.
"This is the first clinical trial for our
company, and we are very much
looking forward to the results," said
Peter Buckel, CEO of SuppreMol. "If
the data are as expected, we are
planning to start a Phase Ib/IIa clinical
trial with SM101 in patients by the
end of this year."
Last year, the European
Commission granted SuppreMol
orphan medicinal product designation
in the EU for SM101 in ITP. The
company recently received significant
BMBF funding for expansion of clinical
applications of SM101.
www.suppremol.com
Ultra-modern equipment is crucial
for security and quality.
SuppreMol's lead product, SM101,
is nearly through phase 0/Ia with
no adverse reactions.
Drug Discovery
Unlocking the therapeutic potential
of Fc-receptors in autoimmune diseases
15
Greater Munich Biotech Region
Drug Discovery
Innovation and expertise for diagnostic serology
Mikrogen develops, produces and distributes test systems for medical laboratory diagnosis in the field of
bacterial and viral infectious diseases, and autoimmune diseases
E
xtensive and accurate
evaluation of test systems, in
collaboration with experts
and scientific institutes, are the
basis for reliable results in routine
serodiagnostics. Mikrogen
specialises in the development,
production and distribution of test
systems for medical laboratory
diagnosis in the fields of bacterial
and viral infectious diseases, and
autoimmune diseases. In addition
Mikrogen provides scientific and
technical know-how and
assistance, and since 1989 has
produced antigens for clinical
diagnostics. The company has
expertise for the development of
test systems based on recombinant
antigens, and owns various patents
particularly for Borrelia
burgdorferi, Parvovirus B19, EBV
and HCV antigens.
The company's skilled and
experienced employees are the key
to its success. To constantly improve
the performance of clinical
diagnostics, more than one hundred
staff members work continuously on
the implementation of the latest
scientific results.
It is the company's philosophy to
develop high-value products
providing additional benefits for its
customers. It attaches great
importance to achieving scientific
excellence as well as outstanding
customer consulting services.
Mikrogen is investing an intensive
research effort into the development
of novel diagnostic technologies. The
future diagnostic platforms will
enable rapid and cost-effective
diagnosis of infectious and
autoimmune diseases. Mikrogen is
engaged in the development of
innovative detection technologies
like chip and micro arrays which
ensure fully automated, high-
throughput and miniaturised
detection of pathogen specific
antibodies and nucleic acids.
www.mikrogen.de
To constantly improve the performance of clinical diagnostics, more
than one hundred Mikrogen staff work on the implementation of the
latest scientific results.
Spin-off is second time around for Corimmun management
C
orimmun GmbH is a private
biotechnology company
located in Martinsried. It was
founded in 2006 as a spin-off from
the Universities of Würzburg
(research groups of Dr Roland Jahns
and Prof Martin Lohse at the Rudolf-
Virchow Centre for Biomedicine and
the Department of Cardiology) and
Tübingen (research groups of Dr
Dorothea Siegel-Axel and Prof
Meinrad Gawaz at the Department
of Cardiology). Seed financing was
obtained from Hightech-
Gründerfonds, Bayernkapital and
BioM. In 2008, series A financing
was secured from MIG Fonds AG
together with the ERP-Startfonds of
the KFW-Bank and Bayernkapital.
Corimmun is a drug development
company which focuses on
inflammatory mechanisms in heart
failure and atherosclerosis, and it
continues to enjoy scientific support
from the university groups of its
founders. Current projects are
funded by two grants from the Go-
Bio programme of the national
ministry of science and education.
Track record
Corimmun´s management had
previously built up and successfully
merged the biotech company
ProCorde with London based Trigen to
form Trigen Holdings AG with
headquarters in Martinsried. Research
activities are carried out at the
university departments, and parallel
drug development is undertaken at the
Corimmun premises in Martinsried.
With the combined activities at
Corimmun, active drugs to treat
patients with life-threatening diseases
are being developed in a highly
competent and efficient process.
Two innovative products COR-1 and
COR-2 are currently in preclinical
development. COR-1 is a peptide drug
candidate to prevent the auto-
antibody-mediated propagation of
heart failure. Functional auto-antibodies
are an increasingly recognised
phenomenon in any form of heart
failure, corresponding to a large and
previously unmet medical need.
COR-2 is a soluble recombinant
therapeutic protein which prevents
foam cell formation in
atherosclerotic plaques with the
potential to reverse plaque
progression.
Parallel service activity
In addition to its drug development
activity, Corimmun provides ELISA-
based assay development on a
fee-for-service basis, eg for the
detection of drugs or other agents or
for antibody detection in blood
samples or other liquids. Corimmun´s
laboratories have been certified
according to good laboratory
practice (GLP) for these
measurements. The assays can be
used for pharmacokinetic studies or
antibody determinations in human or
animal blood samples, eg during
preclinical or clinical studies
www.corimmun.com
Dr Götz Münch, co-founder and
CEO, Corimmun GmbH
Drug development company focuses on inflammatory mechanisms in heart failure and atherosclerosis
16
Greater Munich Biotech Region
Engineering the medicines
of tomorrow
With its unique technologies, MorphoSys AG is
developing the next generation of antibodies
which can be used to treat diseases and for
research and diagnostics purposes.
M
orphoSys is an inde-
pendent
biotechnology
company that
develops novel antibodies for
therapeutic, diagnostic and
research applications.
The company’s core technology
HuCAL
®
, a collection of more than
45 billion functional, distinct, fully
human antibodies, is one of the
most powerful methods available for
the rapid and automated production
of specific antibodies. Its most
distinctive feature is the capability to
optimise antibodies to pre-defined
specifications, allowing MorphoSys’s
researchers and their partners to
‘Engineer the Medicines of
Tomorrow’. By successfully applying
this and other proprietary
technologies, MorphoSys has
become a leader in the field of
therapeutic antibodies, one of the
fastest-growing drug classes in
human healthcare. Through its
business unit AbD Serotec,
MorphoSys is expanding the reach
of its technologies in the diagnostics
and research markets.
Through its alliances with some of
the world’s leading pharmaceutical
companies, MorphoSys has created
a pipeline of more than 60 drug
candidates. The company is
expanding its drug pipeline by
adding new partnered programmes
and by building a portfolio of fully-
owned therapeutic antibodies. For
its proprietary portfolio, the
company focuses on the areas of
oncology and inflammation. Its
most advanced programme is
MOR103, a first-in-class fully
human antibody against GM-CSF.
A central objective of MorphoSys
is to establish its HuCAL technology
as a standard for antibody
generation, spanning the research,
diagnostic and therapeutic markets.
Preferred partners are organisations
with complementary interests,
research, technologies and expertise.
Additionally, MorphoSys intends to
further intensify its internal drug
development efforts. In the second
half of 2009, MorphoSys expects to
start a phase 1b/2a clinical trial for its
most advanced proprietary
compound MOR103 in rheumatoid
arthritis. In total, the company’s
proprietary pipeline will consist of up
to eight HuCAL antibody
programmes by the end of 2009.
Founded in 1992 as a core team
of young researchers, MorphoSys
has grown into a globally operating
organisation with over 370
employees today. The company’s
headquarter in Martinsried near
Munich is embedded into the
Bavarian biotech cluster, allowing a
vivid and active exchange with the
company’s peers and stakeholders.
The advantage of being situated in
the Greater Munich Biotech region
is quick access to well-trained
scientific personnel as well as
interactions with other biotech
companies and the close-by
universities and research institutes.
www.morphosys.com
Founded in 1992 as a core team of young researchers, MorphoSys
has grown into a global organisation with over 370 employees
Discovery Platforms
17
Greater Munich Biotech Region
Discovery Platforms
Supporting small molecule drug development
Kinaxo Biotechnologies offers extensive experience in Cellular Target Profiling
®
and other chemical
proteomics applications.
K
inaxo Biotechnologies is a
privately-held biotechnology
company specialising in
chemical proteomics methods to
support the successful development
of small molecule drugs. As a spin-
off from the Max Planck Institute of
Biochemistry in Martinsried, the
company is expanding and
improving its technology platform in
collaboration with the Max Planck
laboratories of Axel Ullrich, Henrik
Daub and Matthias Mann. These
relationships within the Greater
Munich Biotech Region are of
utmost importance to secure
Kinaxo’s technology leadership.
Kinaxo offers its clients extensive
experience in Cellular Target
Profiling
®
and other chemical
proteomics applications.
The Kinaxo Cellular Target
Profiling
®
service delivers insights into
small molecule target interactions
and binding affinities across the
proteome of any given cell line or
tissue sample. This information
significantly supports decision
making at various stages of the drug
development process, eg lead
compound selection, target
deconvolution, drug reprofiling, and
off-target toxicity assessment.
Kinaxo has experience and
expertise in the drug profiling
applications of mass spectrometry
based chemical proteomics, the core
platform that underpins the Cellular
Target Profiling
®
service. SILAC (Stable
Isotope Labelling by Amino acids in
Cell culture), iTRAQ (Isobaric Tags for
Relative and Absolute Quantitation)
and TMT (Tandem Mass Tags) are
proteome labeling technologies
employed for quantitative mass
spectrometry analysis of cell line and
tissue samples, respectively. The
combination of these technologies
with state-of-the-art proprietary
affinity-based separation and data
processing methods enable the
determination of free compound
affinities to all cellular targets
In April this year, Kinaxo
Biotechnologies GmbH reported that
it successfully applied its technology
to identify the protein kinase mTOR
as a new cellular target of celecoxib
(Celebrex
®
, Pfizer). Celecoxib is a
non-steroidal, anti-inflammatory
Cox-2 inhibitor approved for the
treatment of osteoarthritis,
rheumatoid arthritis and acute pain.
The discovery that celecoxib
targets mTOR contributes to a better
understanding of the drug’s mode of
action and efficacy in cancer
patients. mTOR (mammalian target
of rapamycin) acts as a central
regulator of cell proliferation, cell
survival, angiogenesis and cell
metabolism. Moreover, mTOR is a
key intracellular convergence point
for a number of signalling pathways
that are abnormally activated in
many types of cancer.
As traditional drug development
approaches become more and more
expensive, drug repositioning has
been widely recognised as an
opportunity to expand a drug’s
therapeutic applications. Here,
Cellular Target Profiling
®
provides a
powerful approach to revealing new
targets that indicate additional or
alternative medical uses for clinically
validated or approved drugs.
www.kinaxo.de
Lead compound in Phase II trials for
autoimmune and cancer indications
University spin-off 4SC has three years’ research funding in place to continue
development of its drugs to treat chronic inflammatory diseases and cancer
4
SC AG develops innovative
drug candidates in indications
with high medical need such as
cancer and autoimmune diseases. The
success of 4SC is based on an
experienced development team with
expertise ranging from target
discovery to clinical development, and
its proprietary 4SCan
®
technology.
4SCan
®
provides a solid supply base
for new drug candidates and grants
the company and its partners
undisputed IP and rights for its many
product candidates.
The company was founded in 1997
as a spin-off from the University of
Würzburg and has its premises in
Planegg-Martinsried at the Martinsried
Innovation and Start-up Centre (IZB).
Lead products
4SC-101 is 4SC’s lead compound and is
a novel small molecule of the DMARDs
(disease-modifying anti-rheumatic
drugs) class of drugs recognised for
their role in the treatment of
autoimmune disorders. The substance
acts as a highly selective inhibitor of
the biosynthesis of pyrimidines which
inhibit the proliferation of rapidly
multiplying cells, in particular of
lymphocytes, which are important in the
regulation of the immune response in
IBD. The drug candidate was discovered
by 4SC and has recently commenced a
Phase IIa study in Crohn’s Disease.
Previously, 4SC-101 has already been
successfully tested in a Phase IIa clinical
study in Rheumatoid Arthritis (RA) and
will commence a Phase IIb in RA, in
combination with Methotrexate, in
2009. In addition, the broad therapeutic
potential of 4SC-101 has been further
substantiated in several pre-clinical
studies in chronic inflammatory bowel
diseases, inflammatory skin conditions
and acute transplant rejection.
Resminostat (4SC-201) is 4SC’s
oncology lead product. The
compound is an oral, pan-isotope
histone deacetylase (HDAC) inhibitor.
HDAC inhibitors modify the DNA
structure of tumour cells to cause
their differentiation and programmed
cell death (apoptosis) and are therefore
considered to offer a mechanism of
action that has the potential to halt
tumour progression and induce tumour
regression in order to move towards
therapeutic control of cancers. In a
Phase I trial in multiple cancers, stable
disease was achieved in over 50% of
the patients, whilst the compound was
well tolerated and showed a positive,
differentiating pharmacological profile
to other drugs in this class. In August
4SC started a Phase II trial in
Hepatocellular Carcinoma (HCC). A
further Phase II trial with this
compound is planned in Hodgkin’s
lymphoma this year.
Funding award
Over the next three years, the
company will receive research funding
from the German Federal Ministry of
Education and Research, which will
provide €1.7M to a research
consortium. Joining 4SC AG as
partners in this research project are
quattro research GmbH and Spherotec
GmbH, both from Martinsried, Ludwig
Maximilian University (LMU) of
Munich, the Natural Science and
Medical Institute (NMI) at the
University of Tübingen and the
Centre for Bioinformatics Tübingen.
www.4sc.com
18
Greater Munich Biotech Region
Fragment-based lead generation services
Protein structure driven translation from fragments into lead compounds.
P
roteros is a worldwide
leading company focusing on
X-ray protein structure
analysis, innovative screening
technologies and fragment-based
drug discovery. Successful in
business since 1999, the company
has continuously expanded its client
base and collaborates with more
than 60 international pharma,
biotech and agro companies. It is
privately owned and has been co-
founded by Nobel prize winner Prof
Dr Robert Huber, one of the
pioneers of structural and functional
analysis of proteins. Proteros can
rely on stable long-term financing,
has a positive cash flow and has
shown highly successful and
profitable growth over the last
several years.
The fragment-based drug
discovery activities of Proteros focus
on the translation of structural
biology-derived data into medicinal
chemistry yielding novel lead
structures that qualify for
subsequent lead optimisation.
Proteros uses a tailor-made and
highly optimised fragment-based
lead generation process that is
based on a proprietary in-house
compound library that is highly
enriched with protein
kinase-centric pharmacophores. In
this context, Proteros has
developed a specific skill-set to
design and synthesize kinase
inhibitors of the latest generation
that are specifically targeted to
arrest the enzyme in inactive states.
This offers the opportunity, for
example, to find leads with
improved cellular and in-vivo
efficacy when compared to
traditional ATP-site directed
inhibitors.
www.proteros.com
Expertise in proteomics and classical protein analysis
TOPLAB offers a proprietary proteomics platform spanning from unbiased discovery proteomics with
isotope labeling (ICPL, iTRAQ) or DIGE, to targeted proteomics using MRM.
T
OPLAB provides a GLP
conform technology platform
for contract research and fee-
for-service products with high end
research facilities for proteomics
and protein analytics, target and
biomarker discovery and validation.
The company has outstanding
expertise in proteome analysis,
protein identification and
characterisation with more than 15
years experience, both with its own
scientists and in research
collaborations with leading
academic scientists in the field of
proteomics. A portfolio of
proprietary technologies has been
developed and/or licensed that is
able to significantly enhance the
rate of discovery of potential
diagnostic markers and novel
therapeutic targets.
TOPLAB has gained extensive
experience and expertise in
proteome projects, using stable
isotope labelling techniques like
ICPL™ or iTRAQ for relative or
absolute protein quantification.
Collaborative projects, for example
with the “Blutspendedienst” of the
Bavarian Red Cross, allowed for a
patient specific analysis of plasma.
Samples from patients with colon
cancer were analysed, monitoring
changes in the protein expression
level over a long period of time for
the identification of potential
tumour markers.
As a validation tool, a modern
next generation mass spectrometer
like the QTRAP 5500 offers a time
scheduled targeted proteome
analysis of a large number of
proteins during a single run by MRM
(Multi Reaction Monitoring). The
absolute concentration of a selected
set of proteins can be monitored for
hundreds of patients even at the
lowest concentration levels.
Classical proteome analysis is
done using DIGE for multiplexing
as a highly parallel 2D
electrophoresis method. A DIGE
based, proprietary technique for
HCP analysis has been developed,
allowing for fast and sensitive
identification and quantification of
host cell proteins. The method has
been validated and is approved by
legal authorities.
A key expertise of TOPLAB is the
analysis and characterisation of
recombinant proteins using a set of
methods under GLP conform
conditions. Classical Edman
sequencing as well as mass
spectrometric methods in
combination with nano-HPLC are
applied to analyse, eg, recombinant
antibodies for therapeutic use.
The aim of TOPLAB is to support
its clients with experienced staff,
modern technologies and high end
facilities to achieve confident
results in the shortest time with
calculable costs.
www.toplab.de
Proteros has developed its proprietary Picodropper™ technology to
improve the success rates of protein-ligand-complex structure analysis.
TOPLAB uses ‘next generation’
technology for successful research.
Discovery Platforms
19
Greater Munich Biotech Region
Biopolymers replicate spider silk proteins
Technology developed by AMSilk renders possible large-scale production of natural polymers
A
MSilk GmbH owns a
technology invented at the
Technische Universität
München which enables the
development, improvement and
differentiation of products based on
high performance properties of new
biopolymers, which can now for the
first time be manufactured on an
industrial scale. The unique property-
giving characteristics of these
materials can be manipulated in a
directed fashion at several levels
(protein sequence, covalent
modifications, and assembly of
different spider silk proteins) to
design tailor-made products.
These new products enable
breakthrough changes in the
development of high performance
materials in pharmaceuticals,
cosmetics, composites, and technical
textiles. Tailor-made materials using
the AMSilk technology enable new
and superior products with previously
unachievable features, spanning
multiple industries and applications.
Relocating to
IZB Martinsried
In April AMSilk moved into a new
laboratory for research and applied
technology in the IZB in Martinsried.
“The IZB provided the ideal
conditions for our business. We
needed ready-to-operate laboratory
space where we could begin work
immediately”, said Axel Leimer,
managing director of AMSilk.
The development at the new
laboratory builds on on-going
research co-operations with
universities and other partners. AMSilk
will further establish the development
and large-scale production of spider
silk proteins. It will generate a
comprehensive product portfolio
through its own development and
through joint development with
specific partners or customers. Silk
proteins are always manufactured to
meet clients’ desired specifications.
AMSilk products include
nanoparticles, fibres, specialty films
and non-wovens. The AMSilk
technology renders not only large-
scale production of natural polymers
possible, but, based on a modular
system, also enables a complete
redesign of proteins (protein
engineering) with defined properties
for different applications.
www.amsilk.com
Specialist in all aspects of transfection technology
Biontex supplies complete synthetically manufactured carrier systems and other
high-quality products related to the field of gene technology.
B
iontex Laboratories GmbH was
launched in 1998 as a highly
innovative biotech company in
the field of genetic engineering. The
company's operations focus on
transfection, a field covering the
introduction of genetic material
(transfection) and proteins
(proteofection) into eukaryotic cells.
Biontex has the goal of continuously
improving the success of this
technology by advancing its
synthetically produced carrier systems
for nucleic acids and proteins and
developing a variety of high-quality
genetic engineering products. The
current focus of research is the
development of all-new strategies to
maximise the efficiency of
transfection for any type of cells – in
vivo or in vitro – by means of
synthetic carrier components free
from immunological effects.
Since healthy cells are essential for
successful transfection, Biontex
supplies both carrier reagents and
products which enable mycoplasma-
free cell culture. In addition, it
produces derivatised agaroses for the
purification of appropriately
expressed proteins. The range of
products tailored to the requirements
of microscopy make a significant
contribution to this increasingly
important visualisation method.
In addition to simple operation, the
company focuses on high efficiency
combined with low toxicity and low
immunological effects. For this reason,
all reagents are suitable for use as
valuable aids in biological and
pharmaceutical research. Biontex
products have now been marketed
globally for a decade and some have
been licensed to globally operating
partner companies with great success.
The core of corporate philosophy is
to provide customers with the most
efficient tools for successful transfection
applications. To achieve this Biontex
also establishes unbureaucratic
partnerships with researchers seeking
to test new applications using its
products and thus providing validation.
One further milestone for the
company is the new branch office
Biontex-USA in San Diego, CA, that
has started distributing its products in
North America. This not only
streamlines orders from North
America but offers several advantages
including lower costs, quicker
shipping and technical support.
By continuously improving its non-
viral carrier systems, Biontex‘s ultimate
aim is to help gene therapy to achieve
a breakthrough: this is our vision.
www.biontex.com
Management team at AMSilk, (left to right); Dr Stephan Reschauer, Manager
Patents and Licenses; Axel H Leimer, Managing Director; Dr Lin Römer, Head of R&D
Biontex products have been marketed globally for a decade and some have
been licensed with great success to globally operating partner companies.
Biopharm materials
20
Greater Munich Biotech Region
Formulation development and analytics for biotech drugs
Coriolis PharmaService specialises in conceptual project work to promote the formulation development
process and analytical characterisation for biopharmaceutical drugs
C
oriolis PharmaService GmbH
is a spin-off company of the
Department of Pharmacy -
Pharmaceutical Technology and
Biopharmaceutics of the Ludwig-
Maximilians University (LMU)
Munich, Germany. Early in 2009 the
company moved to its own facilities
in the Innovation and Start-Up
Centre for Biotechnology (IZB) at the
Biotech Campus in Martinsried,
Germany. The initial steps as a
company were supported by a
research grant, but it is now fully
independent of outside funding or
venture capital. As a Contract
Research Organisation for all sizes of
pharmaceutical and biotechnological
companies, Coriolis offers
conceptual project work to promote
the formulation development
process and analytical
characterisation for
biopharmaceutical drugs, with focus
on proteins, monoclonal antibodies
and peptides, but also for other
compounds, such as liposomes,
nanoparticles, microemulsions or
poorly soluble drugs. The
formulation development goes hand
in hand with well established and
modern analytical methods,
including particle and aggregate
characterisation using light blockage,
dynamic light scattering, micro flow
imaging, field flow fractionation, FT-
IR, µ-calorimetry, HPLC methods and
fluorescence techniques. A more
efficient formulation development
with respect to time and material is
achieved by robotic-based high-
throughput screening.
Expertise to reach the market
In close cooperation with its partners
Coriolis has already developed
several formulations for
biopharmaceuticals either in liquid or
in freeze-dried state that have
reached clinical phases. Analytical
methods and drying technologies are
continuously being improved and
expanded through the knowledge
gained from in-house research. The
synergy between specific know-how
within the field of protein
formulation, the variety of analytical
tools used in its labs, and established
as well as innovative drying
technologies (eg freeze-drying,
spray-drying) makes the service of
Coriolis unique. Within the Bavarian
life science cluster where many new
innovative molecules are developed,
Coriolis offers the expertise to
stabilise and formulate these new
proteins, peptides or antibodies to
reach the pharmaceutical market.
www.coriolis-pharma.com
Cells in focus
ibidi GmbH, located in Martinsried, has developed a business which
encompasses the extended needs of cell microscopy.
i
bidi develops, produces and
distributes chambers (µ-Slides) and
accessories for cell based assays.
Besides µ-Slides and µ-Dishes the
product range also covers pump and
heating systems. All ibidi products
are optimised for microscopy.
R&D at ibidi is focussed on three
areas: cell microscopy,
immunofluorescence and cell based
assays. Here, applications like
angiogenesis, chemotaxis, wound
healing and the simulation of blood
vessels are addressed. For these
applications specialised slides and
instruments have been developed,
which allow read-out in microscopy.
Beside µ-Slides, ibidi also provides
integrated systems. Examples are the
perfusion systems which allow
analysis of living cells under flow
conditions and incubation units for
live cell microscopy. That way, the
motion of cells in chemotaxis assays
can be followed over extended
periods of time.
Custom specific designs are
realised via the R&D team, which has
outstanding skills in physics,
chemistry, biology and biotechnology.
As a result the company has
competence and experience in such
fields as cell growth, surface
chemistry and fluidics.
Distribution partnerships
In Germany ibidi has its own sales
force. In other regions it distributes
the product range via a strong
network of partners, ensuring a
presence in all major markets.
Beside the company’s own product
line, ibidi also markets and
distributes on exclusive behalf of
partners: - Applied Biophysics
(impedance measurement systems),
Seahorse (extracellular flux and
bioenergetics), AMG (microscopes)
and KDS (syringe pumps).
ibidi is very pleased to be part of
the Bio-M cluster. Surrounded by
excellent research institutes like the
University of Munich, two Max Planck
Institutes and the general hospital the
company has many ongoing co-
operations. ibidi has also established
in-house partnerships leading to new
product developments, like the new
Transfection kit.
www.ibidi.de
Specialist Services
Technologies are continuously being improved by in-house research
at Coriolis PharmaService GmbH.
Co-culture insert in an ibidi µ-
Dish for wound healing and
invasion assays.
Immunofluorescence staining of
RAT1 fibroblast cells.
21
Greater Munich Biotech Region
Creative technology-driven drug discovery
Origenis offers services for drug design, synthesis, and characterisation driven
by its patented technology platform.
O
rigenis is an established
disease-focused drug design
and discovery company
based in Martinsried. As a part of
the Greater Munich Biotech Region,
the company benefits from the
outstanding local infrastructure and
economic and scientific
environment, and contributes with
its technology to the expertise of
the regional Biotechnology Cluster.
Origenis offers innovative
scientific competence in
combination with a proven, highly
sophisticated research technology,
the MOREsystem
®
. This novel
approach is faster and more
successful than traditional ways of
drug discovery and lead
optimisation. The Origenis
MOREsystem
®
yields more specific
new chemical entities for the
required therapeutic use.
Origenis has achieved seamless
integration of compound design
and synthesis route planning, direct
chemical realisation and analytics,
and immediate biological
characterisation. To fulfill this
ambitious goal, the company has
built an original, patented small
molecule generator that uses
proprietary knowledge base
modelling and multi-parametric
optimisation methods for the design
of target and indication fit. This
enables both drug discovery and
medchem optimisation in one step.
Chemical realisation and biological
validation is performed in house in
1300m
2
of modern equipped and
highly automated lab space. The
MOREsystem
®
has been successfully
applied by leading pharma
companies for many targets in
important therapeutic areas.
In addition to collaborative
research in a variety of therapeutic
areas, Origenis is focusing with its
own projects in the anti-allergic and
anti-inflammatory areas, with two
programmes currently in
preparation for out-licensing.
www.origenis.com
Innovative tools and services for functional gene analysis
Based on its expertise in gene expression and adenoviral technology, SIRION BIOTECH offers a broad
range of R&D in biotechnology and pharmacology for industry and academia.
S
IRION BIOTECH GmbH is a
young biotech company
providing innovative tools and
services for functional gene analysis.
Key competencies are RNA
interference and adenoviral vector
technology. Both strengths have
been combined to develop SIRION
BIOTECH’s RNA interference
technology, Q-tech, allowing
transfection-free siRNA-mediated
RNA interference.
Founded in 2006 by Lars Behrend
and Christian Thirion, both
biochemists with expertise in virology
and cancer biology, the company
started operation in late 2006,
supported by public financing from
Bayern Kapital, KfW and HTGF. It is
based in Martinsried, having its
premises at the IZB, where it has
access to an excellent infrastructure
and biotechnological competence
network. As a young and innovative
company it gains extraordinary
benefits from the proximity to the
high class universities, institutes and
the surrounding biotechnology
cluster of the Munich area. The
technological interchange with
several groups has fostered its
development of new and innovative
vector technology.
Currently, the team consists of 10
scientists and technicians working on
the extension of the Q-tech
programme and developing new
gene analysis services. In near future,
new tools and services will be
offered in the field of micro RNAs
and related fields.
What is Q-tech?
Regardless of strain and type cells
are transfected with a desired siRNA
by SIRION BIOTECH’s technology.
Afterwards cells are frozen and
stored without loss of any RNAi
competence ready for delivery. Upon
arrival, cells can be directly used for
inhibition assays or stored for several
weeks without loss of activity.
Thanks to the adenoviral
transfection technology siRNA is
expressed in cells in a highly
controlled manner. Although cells are
not genetically transformed Q-tech
cells show better and longer lasting
RNAi effects than with conventional
transfection. With Q-tech any kind of
transfection tools become redundant.
Adenovirus technology
Adenoviral vectors are well-established
gene transfer tools for quantitative
gene delivery into mammalian cells.
SIRION BIOTECH’s adenoviral vector
platform allows for efficient knock
down as well as over-expression of
genes even in hard-to-transfect cell
types, including primary cells. SIRION
BIOTECH is able to generate
adenovirus libraries of any size for
functional gene analysis by exploiting
its proprietary high-efficiency in vivo
recombination system.
www.sirion-biotech.de
The Origenis MOREsystem
®
is faster and more successful than
traditional ways of drug discovery and lead optimisation.
SIRION BIOTECH’s Q-tech
technology allows transfection-
free siRNA-mediated RNA
interference.
Specialist Services
22
Greater Munich Biotech Region
F
or the first time in ten years
BIO-Europe, Europe´s largest
partnering event for the life
science industry, returns to
Munich. From 15–17 November
2010 Munich will be the centre of
dealmaking activity for over 2500
biotech, pharmaceutical and
financial executives from around the
world. Equipped with
partneringONE™, the web-based
partnering system for the life science
industry, the BIO-Europe conference
enables delegates to identify, meet
and start partnerships with
companies across the biotech value
chain. Investment and collaboration
opportunities gained at BIO-Europe
conferences have resulted in many
licensing agreements, investments
and M&As. In addition to partnering,
BIO-Europe offers workshops,
panels, company presentations and
an exhibition.
The hosts for the 2010 event, the
Bavarian Ministry of Economic
Affairs, Infrastructure, Transport and
Technology, the BioM Biotech
Cluster Development GmbH and
Bavarian Cluster Biotechnology, will
showcase their historical and
culturally rich city and the diversity of
institutions, global players and
maturing companies powering the
success of biotechnology in the
southern German region.
Munich is home to one of the
largest and most vibrant biotech
clusters in Europe, featuring some
180 life science companies. The
city’s success as a biotech region
can be attributed to a well
developed commercial
biotechnology industry, world-class
scientific research institutions,
excellent infrastructure, efficient
access to capital, and highly
qualified employees.
Even though BIO-Europe 2010 is
still a year away preparations are
proceeding at full speed.
Complementing the daytime
programmes and partnering
sessions, the programme will include
evening events including receptions
at the historic and beautiful Munich
Residenz, Loewenbraeukeller and
Munich Town Hall.
BIO-Europe is produced by EBD
Group, with the support of the
Biotechnology Industry
Organization (BIO).
Event Preview
Welcome to Munich in 2010
Munich will be the venue for BIO-Europe 2010, the well established
bio-event which places networking and partnership facilitating as its
primary aims, alongside workshops, presentations and an exhibition.
About EBD Group
EBD Group is a partnering firm for
the global life science industry. Since
1993, biotech, pharma and medical
device companies have used the
group’s partnering conferences,
technology and services to identify
business opportunities and develop
relationships.
EBD Group’s conferences
include:
• BIO-Europe and BIO-Europe
Spring: Europe’s largest life science
partnering conferences, supported
by the Biotechnology Industry
Organization (BIO)
• ChinaBio Partnering Forum: the
largest life science partnering event
in China
• BioPharm America: the fastest
growing partnering event in North
America
• Biotech Showcase: a forum in
San Francisco for presenting to
investors and business
development executives
• EuroMedtech: EBD Group’s new
partnering event for the medical
technology industry
• BioEquity Europe: an investor
conference organised jointly with
BioCentury Publications and BIO.
EBD Group’s web-based
partnering service,
partneringONE™, is used as the
partnering engine at numerous
third-party events around the
world. Outside of the conference
format, EBD Group’s consultants
provide hands-on assistance for
firms seeking to in- or out-license
products and technologies. EBD
Group has offices in the USA
and Europe.
Want to know more about
BIO-Europe 2010?
In the USA, contact Tom Voigt:
Tel: +1 760 930 0500:
tvoigt@ebdgroup.com
In Europe, contact Annika Rudat:
Tel: +49 89 2388 756-0:
arudat@ebdgroup.com
Meanwhile, don’t forget:
BIO-Europe 2009
Vienna, Austria
Messe Wien Exhibition &
Congress Centre
2–4 November 2009
www.ebdgroup.com/bioeurope
www.ebdgroup.com
Partnering booths at an EBD partnering event
Where the future becomes reality
Our tenants:
4SC AG (DD)· AMSilk GmbH (DD) · amYmed GmbH (DS) · Becton Dickinson GmbH (I) · Bernina Plus & Hartmann Diagnostic Service (DD/DS)· BioM AG (S) ·
BioM Cluster Development GmbH (S) · BioM WB GmbH (S)· Biontex Laboratories GmbH (P) · Coriolis PharmaService GmbH (S) ·
CRELUX GmbH (DD/DS) · DoNatur GmbH (DD) · EKFS Herzchirurgie Prof. Dr. Eissner (DD) · Ella Biotech GmbH (DS) · Emergent BioSolutions GmbH (DD/DS) ·
eticur) GmbH (DS)· Fresenius Biotech GmbH (DD) · Bayerische Gewebebank GmbH (P/S) · ibidi GmbH (DS) · Kinaxo Biotechnologies GmbH (DD) ·
Management Consulting Merx - McM GmbH (S) · MenloSystems GmbH (I) · NanoScape AG (P) · Octagene GmbH (DD/DS) ·
Omegametrix GmbH (DS) · optoSIC GmbH (S) · origenis GmbH (DD/DS) · Prionics Deutschland GmbH (S) · Proteros biostructures GmbH (P/S) ·
quattro research GmbH (DD/DS) · QinLAB Diagnostik (P) · R&D Biopharmaceuticals GmbH (DD/DS) · SiNatur GmbH · siRion BIOTECH GmbH (P/S) ·
Smart Move GmbH (I) · Smartec Ingenieur Büro GmbH (S) · SpheroTec GmbH (DS) · SuppreMol GmbH (DD) · that‘s it gmbh (IT-S) ·
the working group Unternehmensberatung (S)· Trion Research GmbH (DD/DS) · VELUMETRIX GMBH (S) · aromaLab AG (S) · ATRES engineering biogas (S) ·
BioEPS GmbH (S/DS) · Euroderm GmbH (P) · GENidee (DD/DS) · HDBI Hans-Dieter-Belitz-Institut (P/I) · IKINOWO GmbH (DS/P/I/S) · Pieris AG (DD) ·
TUM Biomolecular Food Technology (DD) · UGT Umwelt-Geräte-Technik GmbH (I) · vertis Biotechnologie AG (DD/DS)
DD = Drug Discovery · DS = Diagnostic Services · I = Instruments · IT-S = IT-Services · S = Services status: august 09
HOTSPOT FOR LIFE SCIENCE STARTUPS
www.izb-online.de
Am Klopferspitz 19
82152 Planegg/Martinsried
Tel.: +49 (0) 89 - 700 656 70
Fax: +49 (0) 89 - 700 656 77
Lab and offi ce space (S1 & S2)s
Competitive leasing rentss
Furnished, fl exible roomss
In-house estate managements
The center of an impressive research campuss
(2 excellent universities TU & LMU, Max Planck Institutes for
Biochemistry and Neurobiology, Clinic Großhadern, Gene Center,
Biomedical Center, Prion Center, 40 biotech companies)
Close contacts with investment partnerss
Home for more than 50 startupss
Joint location marketings
Attractive, modern conference rooms s
also for external booking
See you in Munich!
November 15–17, 2010